Automated Author ProfileXU, MINGHUAN
XU, MINGHUAN
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets for this author
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the author's datasets
Total Mentions
Total mentions of the author's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 3.2 (sum of 2 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
This file provides supplementary data for Evaluating the Early Efficacy and Safety of Ritlecitinib in Moderate Alopecia Areata: A Real-World, Single-Center Study. It includes: (1) one illustrative figure demonstrating a representative patient’s clinical response after 16 weeks of treatment, (2) a table summarizing treatment response in eyebrow and eyelash involvement, and (3) a comparative table of baseline demographics and disease characteristics between patients who achieved SALT50 at week 16 and those who did not. These materials support the main findings by offering detailed insights into subgroup responses and potential predictors of efficacy.
Authors
- XU, MINGHUAN ;
- Leong, Hiochon ;
- Zhu, Yifei ;
- Qin, Wang ;
- Ni, Chunya ;
- Tao, Ke ;
- Lin, Jui-Ming ;
- Yang, Kai ;
- Lin, Jinran ;
- Wu, Wenyu
This file provides supplementary data for Evaluating the Early Efficacy and Safety of Ritlecitinib in Moderate Alopecia Areata: A Real-World, Single-Center Study. It includes: (1) one illustrative figure demonstrating a representative patient’s clinical response after 16 weeks of treatment, (2) a table summarizing treatment response in eyebrow and eyelash involvement, and (3) a comparative table of baseline demographics and disease characteristics between patients who achieved SALT50 at week 16 and those who did not. These materials support the main findings by offering detailed insights into subgroup responses and potential predictors of efficacy.
Authors
- XU, MINGHUAN ;
- Leong, Hiochon ;
- Zhu, Yifei ;
- Qin, Wang ;
- Ni, Chunya ;
- Tao, Ke ;
- Lin, Jui-Ming ;
- Yang, Kai ;
- Lin, Jinran ;
- Wu, Wenyu